Gazi University, Department of Internal Medicine, Ankara, TR, Turkey.
Gazi University, Department of Medical Oncology, Ankara, TR, Turkey.
Curr Probl Cancer. 2021 Dec;45(6):100738. doi: 10.1016/j.currproblcancer.2021.100738. Epub 2021 Apr 10.
Brigatinib is a novel potent tyrosine kinase inhibitor as third-generation therapy for anaplastic lymphoma kinase (ALK) rearrangement positive non-small cell lung cancer (NSCLC). Clinical trials show that brigatinib is potent choice of treatment for the first line and further lines of treatment of ALK rearranged NSCLC with highly potent anti-tumor effect on brain metastasis. The adverse effects of brigatinib are tolerable and managable. However, there is limited data about effects on immune system. The most possible serious adverse effect of brigatinib on immune system might be brigatinib associated grade 3-4 lymphopenia. Here we report a brigatinib-induced tuberculosis reactivation patient who is using third-line brigatinib for metastatic NSCLC and have partial response.
布加替尼是一种新型强效酪氨酸激酶抑制剂，作为第三代治疗药物，适用于间变性淋巴瘤激酶（ALK）重排阳性的非小细胞肺癌（NSCLC）。临床试验表明，布加替尼对脑转移具有强效抗肿瘤作用，是 ALK 重排 NSCLC 一线及后线治疗的有力选择。布加替尼的不良反应可耐受且可管理。然而，关于其对免疫系统的影响的数据有限。布加替尼对免疫系统最可能的严重不良反应可能是布加替尼相关性 3-4 级淋巴细胞减少症。在这里，我们报告了一例布加替尼诱导的结核再激活患者，该患者正在使用三线布加替尼治疗转移性 NSCLC，并取得了部分缓解。
